...
首页> 外文期刊>Cell death & disease. >The long noncoding RNA TUG1 is required for TGF-β/TWIST1/EMT-mediated metastasis in colorectal cancer cells
【24h】

The long noncoding RNA TUG1 is required for TGF-β/TWIST1/EMT-mediated metastasis in colorectal cancer cells

机译:在结肠直肠癌细胞中的TGF-β/ Twist1 / EMT介导的转移需要长的非分量RNA Tug1

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide, and metastasis is the major cause of CRC-related mortality. Transforming growth factor-beta (TGF-β) has a central role not only in the regulation of the normal colon but also in the development and metastasis of CRC. However, TGF-β is not considered an ideal therapeutic target because it shows both pro-tumorigenic and anti-tumorigenic activity, depending on the tumor stage. Therefore, it is important to find a downstream signaling component of TGF-β that can be targeted to impair CRC metastasis. Here, we show that TGF-β promotes CRC migration and upregulates the expression of long-noncoding RNA Taurine Upregulated Gene 1 (TUG1). TUG1 knockdown inhibited migration, invasion, and epithelial-mesenchymal transition (EMT) of CRC cells in vitro, and reduced CRC lung metastasis in vivo. TGF-β induced metastasis, and TUG1 knockdown inhibited these effects. In addition, TGF-β could not reverse the anti-metastasis effects of TUG1 knockdown. These data demonstrate that TUG1 is a downstream molecular of TGF-β. Moreover, TWIST1 expression was increased with TGF-β treatment, and TUG1 knockdown decreased TWIST1 expression in CRC cells. TWIST1 knockdown inhibited invasion and EMT in CRC cells; these effects were not changed by simultaneous TUG1 knockdown, indicating that TWIST1 is a downstream mediator of TUG1. Moreover, TUG1 was significantly overexpressed in CRC patients. In conclusion, TGF-β promotes metastasis of CRC via a TUG1/TWIST1/EMT signaling pathway. TUG1 may be a promising drug target to inhibit TGF-β pathway activation in the treatment of CRC.
机译:结肠直肠癌(CRC)是全世界癌症死亡的主要原因之一,转移是CRC相关死亡率的主要原因。转化生长因子-β(TGF-β)不仅具有在正常结肠的调节中的中心作用,而且具有CRC的发育和转移。然而,TGF-β不被认为是理想的治疗目标,因为它表明了促致瘤和抗致致致致致致致致致致致致致致致致致致致致致致致致肿瘤阶段的靶。因此,重要的是找到可以针对损害CRC转移的TGF-β的下游信号分量。在这里,我们表明TGF-β促进CRC迁移,并提出长期性的RNA牛磺酸上调基因1(Tug1)的表达。 Tug1敲低抑制体外CRC细胞的迁移,侵袭和上皮 - 间充质转换(EMT),并减少体内CRC肺转移。 TGF-β诱导的转移,Tug1敲低抑制了这些效果。此外,TGF-β不能扭转Tug1敲低的抗转移效应。这些数据表明Tug1是TGF-β的下游分子。此外,随着TGF-β处理增加了Twist1表达,并且Tug1敲低降低CRC细胞中的Twist1表达。 Twist1敲低抑制CRC细胞中的侵袭和EMT;这些效果不会通过同时Tug1敲低来改变,表明Twist1是Tug1的下游介体。此外,Tug1在CRC患者中显着过表达。总之,TGF-β通过Tug1 / Twist1 / EMT信号通路促进CRC的转移。 Tug1可以是有希望的药物靶标,以抑制CRC治疗的TGF-β途径激活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号